Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262701 · ClinicalTrials.gov registry record · Phase 4
Adjunctive Hydrogen Peroxide for Periodontal Therapy
A Phase 4 study, sponsored by Loma Linda University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT03262701: Clinical Trial Phase 4 study, sponsored by Loma Linda University.
NCT03262701 is a Phase 4 study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 42 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03262701, a Phase 4 study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
There have been many adjunctive treatments for the additional clinical benefits to scaling and root planing (SRP) in the treatment of chronic periodontitis. Topical hydrogen peroxide (HP) delivered in a custom fabricated tray has been shown to improve pocket depth (PD) and inflammation. The purpose of this study is to assess the adjunctive treatment outcome of HP gel in custom tray application in individuals with chronic periodontitis receiving SRP. The purpose of this investigator-initiated study is to evaluate and compare the clinical effects of scaling and root planing (SRP) combined with local delivery of 1.7% hydrogen peroxide (HP) gel in customized trays to that of SRP alone.
Primary Outcome
Periodontal pocket depth reduction as measured by the periodontal probe from the gingival margin to the bottom of the periodontal pocket measured in millimeters.
Interventions
- DRUG Hydrogen Peroxide Gel, 13 weeks
- DRUG Hydrogen Peroxide Gel, 26 weeks
- OTHER Scaling and Root planing group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2021-02-08 |
| Phase | Phase 4 |
Why NCT03262701 stopped before completion
NCT03262701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Hydrogen Peroxide Gel, 13 weeks is the first listed.
NCT03262701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03262701 about?
NCT03262701 is a clinical study titled "Adjunctive Hydrogen Peroxide for Periodontal Therapy". There have been many adjunctive treatments for the additional clinical benefits to scaling and root planing (SRP) in the treatment of chronic periodontitis. Topical hydrogen peroxide (HP) delivered in a custom fabricated tray has been shown to improve pocket depth (PD) and inflammation. The purpose ...
What is the current status of trial NCT03262701?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2018-04-02. Estimated completion is 2021-02-08.
What interventions are being tested in trial NCT03262701?
The interventions under investigation include: Hydrogen Peroxide Gel, 13 weeks (DRUG), Hydrogen Peroxide Gel, 26 weeks (DRUG), Scaling and Root planing group (OTHER).
Who is sponsoring clinical trial NCT03262701?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03262701's enrollment target sits among peer trials
42 1380th of 2000 higher than 611 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI